There is no single maximum duration for Opdivo (nivolumab) that applies to everyone. How long you stay on it depends on your cancer type, whether the drug is working, and how well you tolerate it. For most advanced cancers, the FDA-approved labeling says to continue until the cancer progresses or side effects become unacceptable. For some specific uses, there are hard caps of 1 or 2 years.
Duration Depends on Your Cancer Type
Opdivo is approved for over a dozen cancers, and the recommended treatment length varies significantly across them. Here’s how the major categories break down.
Adjuvant treatment (after surgery): When Opdivo is used to reduce the risk of cancer coming back after surgery, the maximum is typically 1 year. This applies to melanoma, bladder cancer, and esophageal or gastroesophageal junction cancer. You’d stop sooner if the cancer returns or side effects become too severe.
Advanced lung cancer or mesothelioma (with ipilimumab): When Opdivo is combined with ipilimumab for metastatic lung cancer or mesothelioma, treatment can continue for up to 2 years in patients whose cancer hasn’t progressed.
Advanced bladder cancer (first-line, with chemotherapy): After completing up to 6 cycles of combination chemotherapy, Opdivo continues as a single agent for up to 2 years from the first dose.
Advanced melanoma, kidney cancer, liver cancer, and colorectal cancer (with ipilimumab): These start with up to 4 combination doses, then transition to Opdivo alone with no stated time limit. Treatment continues until the cancer grows or side effects require stopping.
Neoadjuvant lung cancer (before surgery): This is the shortest course: 3 to 4 cycles of Opdivo with chemotherapy before surgery, sometimes followed by up to a year of Opdivo afterward.
What the Evidence Says About Stopping at 1 or 2 Years
One of the biggest questions patients and oncologists face is whether it’s safe to stop Opdivo if the cancer is under control. A major clinical trial called CheckMate 153 tested this directly in advanced lung cancer. Patients who were still doing well at the 1-year mark were randomly assigned to either keep going or stop treatment.
The results favored continuing. Among patients whose cancer hadn’t yet progressed, those who kept receiving Opdivo had a median progression-free survival of 24.7 months, compared to 9.4 months for those who stopped at 1 year. At the 2-year mark, 52% of the continuous group remained progression-free versus 31% of those who stopped. Overall survival also diverged over time: 70% of the continuous group were alive at 2 years compared to 57% of those who stopped.
This trial is a key reason many oncologists are cautious about stopping treatment early when it’s working, particularly in advanced lung cancer. That said, continuing treatment also came with more side effects. Serious treatment-related adverse events occurred in about 9% of patients who continued, versus 3% of those who stopped.
Kidney Cancer: No Official Time Limit
Kidney cancer (renal cell carcinoma) is unusual because the pivotal trials for Opdivo didn’t impose a maximum treatment duration. Unlike lung cancer or mesothelioma trials that capped treatment at 2 years, patients with kidney cancer could stay on Opdivo indefinitely. As a result, there are no formal guidelines on when to stop in responding patients.
Emerging data suggests that stopping around 2 years may be reasonable for patients whose tumors have responded well. A study in Acta Oncologica found that patients who electively stopped treatment around 24 months did not have significantly worse outcomes than those who continued. The risk of progression or death was statistically similar between the two groups. Still, this remains a case-by-case decision rather than a standard recommendation.
Long-Term Outcomes in Melanoma
The longest follow-up data comes from advanced melanoma. Final 10-year results from the CheckMate 067 trial showed that 37% of patients treated with Opdivo alone were still alive a decade later, and 43% of those who received the Opdivo-ipilimumab combination survived. No patients were still receiving treatment at the 10-year mark, meaning these survival benefits persisted long after the drug was stopped.
Perhaps the most striking finding: among patients who were progression-free at 3 years, the 10-year melanoma-specific survival rate was 96 to 97%, regardless of whether they received Opdivo alone or in combination. In other words, patients who make it 3 years without their cancer growing have an excellent chance of long-term survival even after treatment ends.
What Causes Treatment to Stop Early
The two main reasons people stop Opdivo before reaching any planned duration are disease progression and immune-related side effects. Opdivo works by releasing the brakes on your immune system, but that same mechanism can cause your immune system to attack healthy tissue.
Life-threatening immune reactions require permanent discontinuation. So do severe immune reactions that keep coming back, or situations where the steroids used to manage side effects can’t be tapered down within about 12 weeks. Common immune-related problems that can force discontinuation include inflammation of the lungs, liver, colon, kidneys, or hormone-producing glands like the thyroid or adrenal glands.
Infusion reactions during treatment can also lead to stopping, though these are less common and can sometimes be managed by slowing the infusion rate.
What Happens If You Restart After Stopping
If your cancer returns after you’ve stopped Opdivo, retreatment is possible but results are mixed. A Japanese study of lung cancer patients who restarted nivolumab after a treatment-free interval found an overall response rate of only about 9%, with a median progression-free survival of 2.6 months. The small number of patients who did respond fared much better, with a median of 11 months before progression.
The length of the treatment-free interval was the strongest predictor of whether retreatment would work. Prior side effects from the first round of immunotherapy did not predict whether serious side effects would occur during retreatment, which is somewhat reassuring for patients who previously had to pause due to immune reactions.
Insurance Reauthorization
Staying on Opdivo long-term also involves practical hurdles. Most insurers, including Aetna and Medicare plans, require precertification and periodic reauthorization. Continuation is generally approved as long as there’s no evidence of disease progression or unacceptable toxicity while on treatment. If your cancer progresses on Opdivo or another checkpoint inhibitor, most insurers will not authorize further treatment with the same class of drug unless specific exceptions apply, such as certain melanoma scenarios. Your oncology team typically handles reauthorization, but it’s worth knowing that ongoing approval is tied directly to whether the treatment is still working.